Business
Expands collaboration with Altreos
Expands collaboration with Altreos.
About this update from Cambridge Cognition Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 9585O Cambridge Cognition Holdings PLC 13 August 2014 \n \n\n \nCambridge Cognition Holdings Plc\n('Cambridge Cognition' or the 'Company')\n \nExpands collaboration with Altreos\n \nCambridge Cognition Holdings plc (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the acceleration of safe and effective medicines in drug development, announces the expanded scientific partnership with Altreos following the release of two draft FDA guidelines on human abuse liability ('HAL') assessments on drugs* and abuse-deterrent products. \n \nThere has been an increased demand for ways of assessing the human abuse potential of new chemical entities (NCE's). In response to this demand, Cambridge Cognition has formed a scientific partnership with Altreos Research Partners, Inc., a leading provider of scientific, regulatory and operational input on abuse liability assessments for NCE's and abuse deterrent formulations. This partnership exists to develop and supply scientific software that will identify the potential for cognitive impairment caused by NCE's and identify new abuse-deterrent products. \n \nAltreos offers a breadth of expertise and research experience having been involved in the design and evaluation of over one hundred Phase 1 studies, including more than 50 abuse liability studies, as well as first-in-man, pharmacokinetic, drug/alcohol interaction and proof of concept studies. At the core of the abuse liability studies, cognitive assessment is undertaken with the newly launched \"cloud\" abuse liability product, CTIS-AL from the Company. \n \nScott Goss, Chief Commercial Officer at Cambridge Cognition stated: \"This is an exciting development in a relationship that has grown significantly in the last year. The aim of the partnership is to maximize the combined benefits of Altreos' knowledge and experience with Cambridge Cognition's industry leading solutions for delivering computerised abuse liability tests to pharmaceutical companies assessing the abuse potential of their product.\n \n\"The Altreos team has already contributed their knowledge and expertise to the development of Cambridge Cognition's newly launched \"cloud\" abuse liability product, CTIS-AL. As part of the partnership, Altreos will continue to support Cambridge ...